MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/01.tp.0000112934.12622.2b

Медицинская библиотека · Transplantation · 2004

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics.

Vieira Carlos A, Agarwal Avinash, Book Benita K, Sidner Richard A, Bearden Christopher M, Gebel Howard M, Roggero Anthony L, Fineberg Naomi S, Taber Timothy, Kraus Michael A, Pescovitz Mark D

СтатьяПоддержка исследования: вне правительства СШАПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Preformed HLA antibodies (Ab), reported as panel-reactive antibody (PRA), prolong patient waiting time for kidney transplantation. We hypothesized that rituximab (RTX) could reduce PRA via B-cell depletion. This initial study reports the safety, pharmacokinetics, and pharmacodynamics of RTX in patients with end-stage renal failure.

METHODS

The study was an investigator-initiated single-dose, dose-escalation phase I trial of RTX in chronic dialysis patients (PRA >50%). It was approved by the Institutional Review Board and the Food and Drug Administration. Nine subjects were treated with a single dose of RTX (n=3 per group) at 50, 150, or 375 mg/m. Peripheral lymphocyte cell surface markers and HLA Ab levels (%PRA and titers) were tested using flow cytometry.

RESULTS

There were four significant adverse events: a suspected histoplasmosis infection; two Tenchkoff dialysis catheter infections; and fever (38.7 degrees C) during infusion. At 2 days after RTX therapy, there was depletion of CD19 cells (pre-RTX 181+/-137 vs. post-RTX 12+/-5.6, P =0.006). In 2 (22%) of 9 subjects, there was no appreciable change in PRA. Among the other seven patients, one had a decrease in PRA from 87% to 51% with a concurrent decrease in fluorescence intensity; five patients had changes in histogram architecture suggesting loss of antibody specificity; and one patient had a fourfold decrease in PRA titer from 1:64 to 1:16 at 6 months after treatment. In addition, one of the seven patients converted a donor-specific crossmatch to negative and underwent a successful living donor kidney transplantation.

CONCLUSIONS

RTX can be safely administered and may be an effective agent to reduce high-titer anti-HLA Abs in subjects awaiting kidney transplantation.

Для цитирования: Vieira Carlos A, Agarwal Avinash, Book Benita K, Sidner Richard A, Bearden Christopher M, Gebel Howard M, Roggero Anthony L, Fineberg Naomi S, Taber Timothy, Kraus Michael A, Pescovitz Mark D. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics.. Transplantation. 2004. DOI: 10.1097/01.tp.0000112934.12622.2b.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.